Download Gene Section SPINK7 (serine peptidase inhibitor, Kazal type 7 (putative))

Atlas of Genetics and Cytogenetics
in Oncology and Haematology
OPEN ACCESS JOURNAL AT INIST-CNRS
Gene Section
Mini Review
SPINK7 (serine peptidase inhibitor, Kazal type 7
(putative))
Xiying Yu, Shih-Hsin Lu
Department of Etiology and Carcinogenesis, Cancer Institute Peking Union, Medical College and Chinese
Academy of Medical Sciences Beijing 100021, P.R. China
Published in Atlas Database: April 2007
Online updated version: http://AtlasGeneticsOncology.org/Genes/SPINK7ID40396ch5q33.html
DOI: 10.4267/2042/15902
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 2007 Atlas of Genetics and Cytogenetics in Oncology and Haematology
Identity
Protein
Hugo: SPINK7
Other names: ECRG2; ECG2; MGC133105;
MGC133106
Location: 5q33.1
Local order: Telomeric to SPINK5L3 and centromeric
to SPINK1.
Note: The N-terminal 1-19 is the single peptide of the
protein. The C-terminal 30-85 of the protein contains a
typical x(8)-C-x(6)-C-x(7)-C-x(6)-Y-x(3)-C-x(2,3)-Cx(17)-C conserve region, coding a Kazal type serine
protease inhibitors (Kazal) domain.
DNA/RNA
Description
The molecular weight of the encoding protein
contained 85 amino acids is about 9.23 kDa. ECRG2
gene contains a typical Kazal serine protease inhibitors
conserved domain about 56 amino acids at its Cterminal and three kinase phosphorlation site (protein
kinase C, Casein kinase II and Tyrosine kinase).
Diagram of ECRG2 gene. Exons are represented by red
boxes. Exons 1 to 4 from 5' to 3' direction.
Description
The ECRG2 gene contains 4 exons and spans about
3540 bp.
Expression
ECRG2 gene was expressed in normal tissues, such as
esophagus, liver, colon and lung. But it was less
expressed in the cancerous tissues, especially low
frequency of expression of ECRG2 gene in esophageal
cancer but was less expressed in the cancerous tissues,
especially low frequency of expression of ECRG2 gene
in esophageal cancer.
Transcription
The full-length of cDNA of ECRG2 gene was revealed
569 bp, the open reading frame (ORF) is 258 bp. The
sequence upstream of the exon-1 upon the
NT_2023158.1 genomic sequence revealed a typical
TATA box contained promotor at 44 bp from the
predicted translation start site. The transcription start
site is just 6 bp upstream of the 5' end sequence.
Localisation
The protein was localized on the cell membrane.
Pseudogene
Function
None.
The expression of ECRG2 can inhibit the migratory
ability of high metastasic tumor cells.
Atlas Genet Cytogenet Oncol Haematol. 2007;11(4)
283
SPINK7 (serine peptidase inhibitor, Kazal type 7 (putative))
Yu X, Lu SH
apoptosis and in various physiological processes.
3. Data suggest that the physical interaction of
esophageal cancer related gene 2 (ECRG2) and
metallothionein2A (MT2A) may play an important role
in the carcinogenesis of esophageal cancer.
Homology
The sequence of the ECRG2 gene did not reveal
remarkable similarity to the known sequence in the
homology analysis with the public database of
GenBank while the deduced amino acid sequence
showed 97% homology to a tumor associated KAZALtype serine protease inhibitor peptide (US patent
5851987).
References
Su T, Liu H, Lu S. Cloning and identification of cDNA
fragments related to human esophageal cancer. Zhonghua
Zhong Liu Za Zhi 1998;20(4):254-257.
Mutations
Cui YP, Wang JB, Zhang XY, Bi MX, Guo LP, Lu SH. Using
yeast two-hybrid system to identify ECRG2 associated proteins
and their possible interactions with ECRG2 gene. World J
Gastroenterol 2003;9(9):1892-1896.
Note: None
Implicated in
Cui Y, Wang J, Zhang X, Lang R, Bi M, Guo L, Lu SH. ECRG2,
a novel candidate of tumor suppressor gene in the esophageal
carcinoma, interacts directly with metallothionein 2A and links
to
apoptosis.
Biochem
Biophys
Res
Commun
2003;302(4):904-915.
Esophageal cancer
Note: Expression profile of ECRG2 gene in 7 normal
esophageal epithelia, 51 esophageal cancers and 33
tumor adjacent tissues were 100%, 21% and 52%
respectively. About 79% of ECRG2 gene was no
expressed in the esophageal cancer. ECRG2 was highly
expressed in the adult normal esophageal tissue, low
expressed in the fetal esophageal tissue and completely
loss of expression in the esophageal cancer and
corresponding adjacent tissues. The results show that
the ECRG2 gene may be a specific gene for
carcinogenesis of esophagus.
The studies provide more evidences on the role of
ECRG2 in the inhibition of tumor cell proliferation,
migration and metastasis, and give a straightforward
way to block enzymatic activity in extra-cellular matrix
to achieve the therapeutic benefit in the tested human
cancers.
1. Short tandem repeat polymorphism in a novel
esophageal cancer-related gene (ECRG2) implicates
susceptibility to esophageal cancer
2. Potential interaction partner for ECRG2 might be
involved in regulation of cell proliferation and
Atlas Genet Cytogenet Oncol Haematol. 2007;11(4)
Yue CM, Bi MX, Tan W, Deng DJ, Zhang XY, Guo LP, Lin DX,
Lu SH. Short tandem repeat polymorphism in a novel
esophageal cancer-related gene (ECRG2) implicates
susceptibility to esophageal cancer in Chinese population. Int J
Cancer 2004;108(2):232-236.
Huang G, Wang D, Guo L, Zhao N, Li Y, Lu SH. Monoclonal
antibodies to esophageal cancer-related gene2 protein.
Hybridoma (Larchmt) 2005;24(2):86-91.
Li MN, Huang G, Guo LP, Lu SH. Inhibitory effects of
esophageal cancer related gene 2 on proliferation of human
esophageal cancer cell EC9706. Zhonghua Yi Xue Za Zhi
2005;85(39):2785-2788.
Kaifi JT, Cataldegirmen G, Wachowiak R, Schurr PG,
Kleinhans H, Kosti G, Yekebas EF, Mann O, Kutup A, Kalinin
V, Strate T, Izbicki JR. Short tandem repeat polymorphisms of
exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma
and chronic pancreatitis. Anticancer Res 2007;27(1A):69-73.
This article should be referenced as such:
Yu X, Lu SH. SPINK7 (serine peptidase inhibitor, Kazal type 7
(putative)). Atlas Genet Cytogenet Oncol Haematol.2007;
11(4):283-284.
284